GEXVal CEO to Present at the Workshop on Fragile X Syndrome & Neurodevelopmental Disorders in the Netherlands

GEXVal Inc.
September 16, 2025

GEXVal CEO to Present at 21st Workshop on Fragile X syndrome & other Neurodevelopmental Disorders in the Netherlands

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that President and CEO Dr. Juran Kato will present at 21st Workshop on Fragile X syndrome & other Neurodevelopmental Disorders in Noordwijk, the Netherlands, following an invitation from the organizers.

[Event Overview]
Since 1983, this workshop has been driving breakthroughs in Fragile X syndrome and neurodevelopmental disorders research. For over four decades, it has served as a premier international forum where scientists share cutting-edge findings on various genetic disorders, bridging the gap between laboratory discoveries and real-world treatments to accelerate the development of new therapies.
This unique gathering brings together a diverse community of researchers, clinicians, pharmaceutical professionals, and patient advocates from across the globe. Through dynamic presentations and collaborative roundtable discussions, participants work together to advance treatment options for neurodevelopmental disorders. Having traveled to venues across North America, Europe, Oceania, and South America, this marks the 21st edition of this influential conference.

**Presentation Details**

[CEO Statement]
President and CEO Dr. Juran Kato states: "We are deeply honored to participate in this gathering of international researchers dedicated to neurodevelopmental disorders. At GEXVal, we are tackling drug development for Fragile X syndrome and other conditions through our Global Program Team, comprising drug discovery experts from Japan, Germany, the United Kingdom, and the United States.
We are excited to share our findings with stakeholders involved in developing treatments for rare diseases. Through such collaborations, we anticipate that international research networks will continue to flourish, accelerating our collective efforts to deliver new treatment options to patients and their families. We extend our sincere gratitude to the organizers for providing this valuable opportunity."

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com